1,042 research outputs found
Multiple Synchronous Squamous Cell Cancers of the Skin and Esophagus: Differential Management of Primary Versus Secondary Tumor
No full textMultiple primary tumors are uncommon in patients with squamous cell esophageal cancer. Conventional imaging methods have limitations in detecting those tumors. Although 18-F-fluoro-deoxyglucose-positron emission tomography scanner increases the detection of multiple synchronous tumors in patients with other malignancies, its contribution in patients with squamous cell esophageal cancer has not been assessed as it is not systematically performed. The detection of synchronous skin squamous cell tumors in patients with squamous cell esophageal cancer presents a challenge for making diagnostic and therapeutic decisions. A metastatic tumor leads to palliative management, whereas the diagnosis of a primary skin tumor requires curative treatment of both squamous cell tumors. Pathological evaluation appears crucial in the decision
A Cost Analysis of Healthcare Episodes Including Day-Case Bariatric Surgery (Roux-en-Y Gastric Bypass and Sleeve Gastrectomy) Versus Inpatient Surgery
No full textY Background Assessing the medico-economic outcomes of a healthcare pathway including day-case bariatric surgery versus the conventional pathway.Methods This economical evaluation is a prospective cohort study with historical controls. Between March 2019 and December 2020, 30 patients eligible for bariatric surgery were considered in the day-case group. Surgical procedures included sleeve gastrectomy and Roux-en-Y gastric bypass. The day-case pathway included patient education, post-discharge follow-up by a community nurse twice-daily and standardized communications to surgeons. Day-case patients were paired with 30 inpatients, based on the type of intervention, age, and ASA status. The primary outcome was the cost of care episodes from the preoperative visit to the 30-day postoperative visit. Micro-costing methodology and activity-based costing were used. Secondary outcomes included length of hospital stay, rate of unanticipated events, and patient' satisfaction assessment.Results Male-to-female ratio was 1/2. In the day-case versus inpatient group, age, number of associated medical conditions, and BMI (42.9 +/- 4.9 versus 42.6 +/- 4.6, p > 0.05) were similar. In the day-case group, there were 7 overnight stays (23.3%), 3 readmissions (10%), and 4 unscheduled consultations (13.3%). The overall length of hospital stay was significantly shorter (0.65 +/- 0.33, versus 2.9 +/- 0.4 days, p < 0.0001). The complication rate was 6.6% in both groups. The cost of the care episode was euro 4272.9 +/- 589.7 for the day-case group versus euro 4993.7 +/- 695.6 for inpatients, corresponding to a 14.4% cost reduction (p = 0.0254).Conclusions Day-case bariatric surgery appears to be safe and beneficial in terms of costs. It involves a specific organization with postdischarge follow-up. Graphical abstrac
Supplementary_Table_6._PYY – Supplemental material for Gastrointestinal Hormones Manipulation to Counteract Metabolic Syndrome Using Duodenal Targeted Embolization
No full textSupplemental material, Supplementary_Table_6._PYY for Gastrointestinal Hormones Manipulation to Counteract Metabolic Syndrome Using Duodenal Targeted Embolization by Raoul Pop, Seong-Ho Kong, Allan Langlois, Francesco Marchegiani, Eran Shlomovitz, András Legnèr, William Bietiger, Michel Pinget, Rémy Beaujeux, Didier Mutter, Jacques Marescaux and Michele Diana in Surgical Innovation</p
Supplementary_Table_5._GLP1 – Supplemental material for Gastrointestinal Hormones Manipulation to Counteract Metabolic Syndrome Using Duodenal Targeted Embolization
No full textSupplemental material, Supplementary_Table_5._GLP1 for Gastrointestinal Hormones Manipulation to Counteract Metabolic Syndrome Using Duodenal Targeted Embolization by Raoul Pop, Seong-Ho Kong, Allan Langlois, Francesco Marchegiani, Eran Shlomovitz, András Legnèr, William Bietiger, Michel Pinget, Rémy Beaujeux, Didier Mutter, Jacques Marescaux and Michele Diana in Surgical Innovation</p
Supplementary_Table_7._RNA_SGLT-1 – Supplemental material for Gastrointestinal Hormones Manipulation to Counteract Metabolic Syndrome Using Duodenal Targeted Embolization
No full textSupplemental material, Supplementary_Table_7._RNA_SGLT-1 for Gastrointestinal Hormones Manipulation to Counteract Metabolic Syndrome Using Duodenal Targeted Embolization by Raoul Pop, Seong-Ho Kong, Allan Langlois, Francesco Marchegiani, Eran Shlomovitz, András Legnèr, William Bietiger, Michel Pinget, Rémy Beaujeux, Didier Mutter, Jacques Marescaux and Michele Diana in Surgical Innovation</p
Supplementary_Table_4._GIP – Supplemental material for Gastrointestinal Hormones Manipulation to Counteract Metabolic Syndrome Using Duodenal Targeted Embolization
No full textSupplemental material, Supplementary_Table_4._GIP for Gastrointestinal Hormones Manipulation to Counteract Metabolic Syndrome Using Duodenal Targeted Embolization by Raoul Pop, Seong-Ho Kong, Allan Langlois, Francesco Marchegiani, Eran Shlomovitz, András Legnèr, William Bietiger, Michel Pinget, Rémy Beaujeux, Didier Mutter, Jacques Marescaux and Michele Diana in Surgical Innovation</p
Supplementary_Table_8._RNA_GLUT-2 – Supplemental material for Gastrointestinal Hormones Manipulation to Counteract Metabolic Syndrome Using Duodenal Targeted Embolization
No full textSupplemental material, Supplementary_Table_8._RNA_GLUT-2 for Gastrointestinal Hormones Manipulation to Counteract Metabolic Syndrome Using Duodenal Targeted Embolization by Raoul Pop, Seong-Ho Kong, Allan Langlois, Francesco Marchegiani, Eran Shlomovitz, András Legnèr, William Bietiger, Michel Pinget, Rémy Beaujeux, Didier Mutter, Jacques Marescaux and Michele Diana in Surgical Innovation</p
Supplementary_Table_2._Insulin – Supplemental material for Gastrointestinal Hormones Manipulation to Counteract Metabolic Syndrome Using Duodenal Targeted Embolization
No full textSupplemental material, Supplementary_Table_2._Insulin for Gastrointestinal Hormones Manipulation to Counteract Metabolic Syndrome Using Duodenal Targeted Embolization by Raoul Pop, Seong-Ho Kong, Allan Langlois, Francesco Marchegiani, Eran Shlomovitz, András Legnèr, William Bietiger, Michel Pinget, Rémy Beaujeux, Didier Mutter, Jacques Marescaux and Michele Diana in Surgical Innovation</p
Supplementary_Table_1._Ghrelin – Supplemental material for Gastrointestinal Hormones Manipulation to Counteract Metabolic Syndrome Using Duodenal Targeted Embolization
No full textSupplemental material, Supplementary_Table_1._Ghrelin for Gastrointestinal Hormones Manipulation to Counteract Metabolic Syndrome Using Duodenal Targeted Embolization by Raoul Pop, Seong-Ho Kong, Allan Langlois, Francesco Marchegiani, Eran Shlomovitz, András Legnèr, William Bietiger, Michel Pinget, Rémy Beaujeux, Didier Mutter, Jacques Marescaux and Michele Diana in Surgical Innovation</p
Supplementary_Table_3._Leptin – Supplemental material for Gastrointestinal Hormones Manipulation to Counteract Metabolic Syndrome Using Duodenal Targeted Embolization
No full textSupplemental material, Supplementary_Table_3._Leptin for Gastrointestinal Hormones Manipulation to Counteract Metabolic Syndrome Using Duodenal Targeted Embolization by Raoul Pop, Seong-Ho Kong, Allan Langlois, Francesco Marchegiani, Eran Shlomovitz, András Legnèr, William Bietiger, Michel Pinget, Rémy Beaujeux, Didier Mutter, Jacques Marescaux and Michele Diana in Surgical Innovation</p
- …
